Related Experiment Video
Updated: May 5, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
SARS-CoV-2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro
Sara Protić1, Milica Crnoglavac Popović1, Nevena Kaličanin2
1Faculty of Chemistry, University of Belgrade, Studentski Trg 12-16, Belgrade, Serbia.
None:
The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin's antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.
More Related Videos
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis

